Edison Pharmaceuticals, Inc.

Ptc Therapeutics, Inc.

Bioelectron Technology Corporation

Conopco, Inc.

Unilever, N.v.

Unilever Plc, a Company Registered in England and Wales Under Company No. 41424 of

Andrew W Hinman

Kieron E Wesson

Orion D Jankowski

William Dvorak Shrader

Paul Mollard

Dana Davis

Jeffrey K Trimmer

Charles R Holst

Eric Torrey

Angela Minnella

Steven J Richards

Sean Pintchovski

Viktoria Kheifets

Christopher R Cornell

Edgar P Lee

Kieron W Wesson

Angela Minella

Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of &#x3b1;-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.

2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders

Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are tocopherol quinone derivatives. Further disclosed are compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure.

Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.

Process for the production of alpha-tocotrienol and derivatives

2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders

Provided herein are methods and compositions comprising resorcinol derivatives for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible discontinuities of the skin resulting from skin pigmentation, skin aging, or other disorders are also disclosed.

Resorcinol compounds for dermatological use

Disclosed herein are alkyl-heteroaryl substituted quinone derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. 

Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders

Disclosed herein are phenazine-3-one and phenothiazine-3-one derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.

Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders

Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. 

Resorufin derivatives for treatment of oxidative stress disorders

Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compound is a compound of Formula I or Formula II: wherein: Rand Rare independently hydrogen, (C-C)alkyl or &#x2014;O(C-C)alkyl; or Rand Rtogether represent &#x2014;CH&#x2550;CH&#x2014;CH&#x2550;CH&#x2014;; Ris (C1-C6)alkyl; X is &#x2014;CH&#x2550;CH&#x2014; or &#x2014;C&#x2261;C&#x2014;; m is 1-10; n is 1-5; k is 1-3, with the proviso that when k is an integer of 2 or 3, n is independently 1-5 in each occurrence of the &#x2014;X&#x2014;(CH)&#x2014; group; Y is &#x2014;OR, &#x2014;CN, &#x2014;C(&#x2550;O)OR, &#x2014;C(&#x2550;O)R, or &#x2014;C(&#x2550;O)N(R); Rand Rare independently selected from the group consisting of hydrogen, &#x2014;(C-C)alkyl, &#x2014;(C-C)haloalkyl, &#x2014;C(&#x2550;O)&#x2014;(C-C)alkyl, &#x2014;C(&#x2550;O)&#x2014;(C-C)haloalkyl, &#x2014;C(&#x2550;O)&#x2014;NH(C-C)alkyl, &#x2014;C(&#x2550;O)&#x2014;N((C-C)alkyl), &#x2014;C(&#x2550;O)&#x2014;NH, and phenyl, wherein the phenyl group may optionally be substituted with a substituent selected from the group consisting of &#x2014;(C-C)alkyl, &#x2014;O&#x2014;(C-C)alkyl, &#x2014;(C-C)haloalkyl, and halo; each Ris independently hydrogen or &#x2014;(C-C)alkyl; and M is &#x2014;H, &#x2014;C(O)&#x2014;Ror &#x2014;C(O)O&#x2014;R, wherein Ris &#x2014;(C-C)alkyl or phenyl; or a stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, crystalline form, non-crystalline form, hydrate or solvate thereof. 

Benzoquinone derivatives for treating oxidative stress disorders

Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

(Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases

Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.

Growing community of inventors

San Francisco, CA, United States of America

Andrew W Hinman